

Form 605
Corporations Act 2001
Section 671B

Notice of ceasing to be a substantial holder

To Company Name/Scheme Actinogen Medical Limited

ACN/ARSN 086 778 476

1. Details of substantial holder (1)

Name BVF Partners L.P. on its own behalf and on behalf of BVF Inc. and Mark N. Lampert

ACN/ARSN (if applicable) _____

The holder ceased to be a
substantial holder on

22/4/2025, 23/4/2025, 24/4/2025, 25/4/2025, 30/4/2025, 1/5/2025, 2/5/2025,
5/5/2025, 6/5/2025, 7/5/2025, 8/5/2025, 9/5/2025, 13/5/2025, 16/5/2025 and
19/5/2025

The previous notice was given to the company on 23/4/2025

The previous notice was dated 23/4/2025

2. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change (5)	Class (6) and number of securities affected	Person's votes affected
22/4/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$1,153.13	42,324 fully paid ordinary shares	42,324
22/4/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$263.63	9,676 fully paid ordinary shares	9,676
23/4/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$3,768.78	134,869 fully paid ordinary shares	134,869
23/4/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$3,496.66	125,131 fully paid ordinary shares	125,131
24/4/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$7,636.89	280,300 fully paid ordinary shares	280,300
24/4/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$4,623.54	169,700 fully paid ordinary shares	169,700
25/4/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$10,852.93	396,886 fully paid ordinary shares	396,886
25/4/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$6,046.40	221,114 fully paid ordinary shares	221,114

30/4/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$24,952.56	939,946 fully paid ordinary shares	939,946
30/4/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$17,697.72	666,661 fully paid ordinary shares	666,661
1/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$23,270.44	900,273 fully paid ordinary shares	900,273
1/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$16,933.16	655,100 fully paid ordinary shares	655,100
2/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$24,086.13	928,246 fully paid ordinary shares	928,246
2/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$903.15	34,806 fully paid ordinary shares	34,806
5/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$2,316.12	87,576 fully paid ordinary shares	87,576
5/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$4,685.96	177,183 fully paid ordinary shares	177,183
5/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$2,012.14	76,082 fully paid ordinary shares	76,082
5/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$505.32	19,107 fully paid ordinary shares	19,107
6/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$12,078.77	465,499 fully paid ordinary shares	465,499
6/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$8,992.51	346,559 fully paid ordinary shares	346,559
6/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$1,425.63	54,942 fully paid ordinary shares	54,942
7/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$5,529.38	211,468 fully paid ordinary shares	211,468
7/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$3,020.52	115,518 fully paid ordinary shares	115,518
7/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$863.24	33,014 fully paid ordinary shares	33,014
8/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$16,999.19	678,616 fully paid ordinary shares	678,616

8/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$13,879.79	554,088 fully paid ordinary shares	554,088
8/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$1,413.23	56,417 fully paid ordinary shares	56,417
8/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$272.52	10,879 fully paid ordinary shares	10,879
9/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$14,752.39	572,944 fully paid ordinary shares	572,944
9/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$15,932.05	618,759 fully paid ordinary shares	618,759
9/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$213.63	8,297 fully paid ordinary shares	8,297
13/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$54,015.47	2,004,582 fully paid ordinary shares	2,004,582
13/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$37,930.38	1,407,644 fully paid ordinary shares	1,407,644
13/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$6,424.17	238,409 fully paid ordinary shares	238,409
13/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$2,418.91	89,769 fully paid ordinary shares	89,769
16/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$32,815.26	1,299,645 fully paid ordinary shares	1,299,645
16/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$19,676.81	779,298 fully paid ordinary shares	779,298
16/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$1,870.68	74,088 fully paid ordinary shares	74,088
16/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$1,208.79	47,874 fully paid ordinary shares	47,874
19/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF I GP LLC and Biotechnology Value Fund, L.P.	On Market sale of fully paid ordinary shares	\$1,812,169.84	95,568,497 fully paid ordinary shares	95,568,497
19/5/2025	BVF Partners L.P., BVF Inc., Mark N. Lampert, BVF II GP LLC and Biotechnology Value Fund II, L.P	On Market sale of fully paid ordinary shares	\$1,382,436.44	72,905,624 fully paid ordinary shares	72,905,624
19/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS Ltd., and Biotechnology Value Trading Fund OS LP	On Market sale of fully paid ordinary shares	\$196,494.76	10,362,555 fully paid ordinary shares	10,362,555

19/5/2025	BVF Partners L.P., BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	\$73,461.40	3,874,138 fully paid ordinary shares	3,874,138
-----------	---	--	-------------	--------------------------------------	-----------

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Not applicable	Not applicable


4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
BVF Partners LP Biotechnology Value Fund, L.P. Biotechnology Value Fund II, L.P. BVF Inc.	44 Montgomery Street, 40 th Floor San Francisco, California 94104 United States of America
BVF Partners OS, Ltd Biotechnology Value Trading Fund OS, L.P.	PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands
Investment 10 LLC	900 North Michigan Avenue, Suite 1100 Chicago, Illinois 60611 United States of America
MSI BVF SPV, LLC	c/o Magnitude Capital, L.L.C. 200 Park Avenue, 56 th Floor New York, NY 10166
Mark N. Lampert	c/o BVF Inc 44 Montgomery Street, 40 th Floor San Francisco, California 94104 United States of America

Signature

print name BVF Partners LP BY BVF Inc., its general partner, BY Mark N. Lampert, capacity General Partner and Attorney-in-Fact for the Substantial Holders

sign here  date 21/5/2025